fda warning letters compounded semaglutide october 2025 Why the Issued 30 to Telehealth Sites Marketing GLP-1s US FDA sends 25 letters

Additionally, advancements in gene-editing technologies, such as CRISPR, could enable precise genetic modifications to enhance L-cell functionality and proliferation

Glucagon-like peptide-1 receptor agonists (GLP-1RAs or GLP-1) medications have skyrocketed into popularity over the past few years

Our findings offer comprehensive real-world evidence for the cardiovascular effectiveness of tirzepatide in clinical practice in the absence of studies with direct comparisons to semaglutide, and ahead of further evidence from the SURPASS-CVOT randomized controlled trial that compared tirzepatide against an older GLP-1 receptor agonist that is not frequently used in routine care 14,17

But the math shows why time-limited coverage is appealing to payers that struggle to pay for beneficiaries' GLP-1 prescriptions, said Michelle Gourdine, chief medical officer for the pharmacy benefit manager CVS Caremark